Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by Sarb99on Nov 09, 2020 11:55am
115 Views
Post# 31863181

RE:RE:RE:RE:Vaccine

RE:RE:RE:RE:Vaccine

Will the world have a vaccine in 2020?

The vaccine candidate is one of many that governments hope to fast-track approval for using emergency powers, and Pfizer and BioNTech have said they will be in a position to publish the data needed to get the green light from the US Food & Drug Administration ‘by the third week of November’.

Although the candidate could be the first widely accepted vaccine to be approved, the trial will continue to monitor participants for the next two years to ensure it is safe over the long term. Meanwhile, the pair are drawing up plans to outline how the vaccine will be produced if its approved.

Ultimately, if everything goes to plan, the pair are hoping to produce up to 50 million doses of the vaccine by the end of 2020, before raising the stakes by producing 1.3 billion doses in 2021. It is important to remember that the trial suggests people will need two doses of the vaccine for it to work, meaning there is only enough capacity at present to potentially treat around 650 million people by the end of next year.

https://www.ig.com/en-ch/news-and-trade-ideas/pfizer-and-biontech-make-breakthrough-with-coronavirus-vaccine-201109



Investing4 wrote:
I wonder if people will need to have two doses. Obviously that will cut the amount of people being treated by half. Either way, it's great news for the world and the economy based on these early results. Just as obvious is the need for testing through this as well. I agree, either way QSC is in good shape. Looking forward to the upcoming webinar and seeing the cubes rolled out across the states. Even at 38% capacity for each cube this stock looks good in my opinion.


<< Previous
Bullboard Posts
Next >>